Synthetic Biology and the Translational Imperative.
Advances at the interface between the biological sciences and engineering are giving rise to emerging research fields such as synthetic biology. Harnessing the potential of synthetic biology requires timely and adequate translation into clinical practice. However, the translational research enterpri...
| Publicado en: | Science & Engineering Ethics Vol. 25; no. 1; pp. 33 - 53 |
|---|---|
| Autores principales: | , , , |
| Formato: | Artículo |
| Publicado: |
Springer Nature
Feb2019
|
| Materias: | |
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=hlh&AN=135326479&site=ehost-live header: @attributes: shortDbName: hlh uiTerm: 135326479 longDbName: Humanities International Complete uiTag: AN controlInfo: bkinfo: jinfo: jid: 13533452 GNI jtl: Science & Engineering Ethics issn: 13533452 maglogo: N pubinfo: dt: Feb2019 vid: 25 iid: 1 pid: 237 pub: Springer Nature artinfo: ui: 135326479 10.1007/s11948-017-0011-3 ppf: 33 ppct: 20 formats: fmt: – @attributes: type: T – @attributes: type: P size: 621KB tig: atl: Synthetic Biology and the Translational Imperative. aug: au: Heidari Feidt, Raheleh Ienca, Marcello Elger, Bernice Simone Folcher, Marc affil: Institute for Biomedical Ethics, Universität Basel, Bernoullistrasse 28, 4056, Basel, Switzerland Health Ethics & Policy Lab, Department of Health Sciences and Technology (D-HEST), ETH Zürich, Auf der Mauer 17, 8001, Zurich, Switzerland Center for Legal Medicine, University of Geneva, Geneva, Switzerland Department of Biosystems Science and Engineering (D-BSSE), ETH Zürich, Mattenstrasse 26, 4058, Basel, Switzerland su: Synthetic biology Life sciences Engineering Biological research Public health Translational research sug: subj: Synthetic biology Life sciences Engineering Biological research Public health Translational research keyword: First-in-human trials Translational imperative ab: Advances at the interface between the biological sciences and engineering are giving rise to emerging research fields such as synthetic biology. Harnessing the potential of synthetic biology requires timely and adequate translation into clinical practice. However, the translational research enterprise is currently facing fundamental obstacles that slow down the transition of scientific discoveries from the laboratory to the patient bedside. These obstacles including scarce financial resources and deficiency of organizational and logistic settings are widely discussed as primary impediments to translational research. In addition, a number of socio-ethical considerations inherent in translational research need to be addressed. As the translational capacity of synthetic biology is tightly linked to its social acceptance and ethical approval, ethical limitations may—together with financial and organizational problems—be co-determinants of suboptimal translation. Therefore, an early assessment of such limitations will contribute to proactively favor successful translation and prevent the promising potential of synthetic biology from remaining under-expressed. Through the discussion of two case-specific inventions in synthetic biology and their associated ethical implications, we illustrate the socio-ethical challenges ahead in the process of implementing synthetic biology into clinical practice. Since reducing the translational lag is essential for delivering the benefits of basic biomedical research to society at large and promoting global health, we advocate a moral obligation to accelerating translational research: the "translational imperative." pubtype: Academic Journal doctype: Article src: R language: English refInfo: copyright: @attributes: flag: Y custom: Science & Engineering Ethics is a copyright of Springer, 2019. All Rights Reserved. item: Science & Engineering Ethics holder: Springer Nature dt: @attributes: year: 2019 holdings: @attributes: islocal: N |
|---|